Payment overview · 2025
General Payments
$190.82
11 reported records · 7 companies
Healthcare provider profile · identity verified
Christy Hearne, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · ASHEBORO, NC · NPI 1760885271
Verified facts
What the public records show
CMS Open Payments records show Christy Hearne, NP received $190.82 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.89 | 29.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.03 | 19.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.86 | 17.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.31 | 9.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.89 | 8.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.98 | 7.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.86 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.82 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.89 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 336 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 34 |
| Potassium Chloride | Potassium Chloride | 260 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 236 | 28 |
| Memantine Hcl | Memantine Hcl | 233 | 33 |
| Furosemide | Furosemide | 225 | 42 |
| Lorazepam | Lorazepam | 206 | 43 |
| Lisinopril | Lisinopril | 192 | 26 |
| Sertraline Hcl | Sertraline Hcl | 184 | 30 |
| Eliquis | Apixaban | 178 | 24 |
| Omeprazole | Omeprazole | 167 | 23 |
| Trazodone Hcl | Trazodone Hcl | 167 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 22 |
| Mirtazapine | Mirtazapine | 139 | 19 |
| Famotidine | Famotidine | 110 | 14 |
| Losartan Potassium | Losartan Potassium | 106 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 19 |
| Gabapentin | Gabapentin | 104 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 17 |
| Alprazolam | Alprazolam | 93 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 11 |
| Myrbetriq | Mirabegron | 84 | 11 |
| Divalproex Sodium | Divalproex Sodium | 83 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | suppressed |
| Latanoprost | Latanoprost | 73 | suppressed |
| Celecoxib | Celecoxib | 72 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 71 | suppressed |
| Metformin Hcl | Metformin Hcl | 70 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 62 | suppressed |
| Allopurinol | Allopurinol | 56 | suppressed |
| Carvedilol | Carvedilol | 51 | suppressed |
| Risperidone | Risperidone | 50 | suppressed |
| Valsartan | Valsartan | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Trimethoprim | Trimethoprim | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Prednisone | Prednisone | 31 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.82 · 11 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, Kerendia, LEQEMBI, Ozempic, REXULTI, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error